ACHN Achillion Pharmaceuticals Inc.

3.86
+0.12  (3%)
Previous Close 3.74
Open 3.74
Price To book 1.46
Market Cap 527899795
Shares 136,761,605
Volume 1,301,725
Short Ratio 4.05
Av. Daily Volume 2,003,619

SEC filingsSee all SEC filings

  1. 8-K - Current report 171077918
  2. 8-K - Current report 171077916
  3. 8-K - Current report 171014674
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014668
  5. 8-K - Current report 17957876

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 initiation announced April 6, 2017. Interim data released August 8, 2017.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)

Latest News

  1. Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
  2. Achillion's HCV Partnership with J&J Terminated, Stock Falls
  3. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : September 12, 2017
  4. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Idera Pharmaceuticals
  5. Why Achillion Pharmaceuticals Crashed 22.2% Today
  6. Achillion Shares Are Plunging on Termination of Hepatitis C Pact
  7. Achillion Pharma Slides After Hep C Deal Is Terminated
  8. Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends
  9. Achillion Announces Strengthening of Management Team
  10. Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen
  11. Edited Transcript of ACHN earnings conference call or presentation 8-Aug-17 8:05pm GMT
  12. Corporate News Blog - Achillion Announces Proof-of-Concept with a First-in-Class, Oral Factor D Inhibitor
  13. Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence
  14. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : August 10, 2017
  15. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals
  16. 2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
  17. Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
  18. These Two Biotech Stocks Are Going Berserk on Wednesday
  19. 3 Biotech Stocks Under the Microscope on Wednesday 8/9/17
  20. Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update

SEC Filings

  1. 8-K - Current report 171077918
  2. 8-K - Current report 171077916
  3. 8-K - Current report 171014674
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014668
  5. 8-K - Current report 17957876
  6. 8-K - Current report 17867451
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17822906
  8. 8-K - Current report 17814813
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814763
  10. EFFECT - Notice of Effectiveness 17798317